|
|
 |
|
 |
|
|
|
|
Title:
|
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed by Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC) - IRB# 09-47A
|
|
Treatments:
|
Capecitabine, Gemcitabine, Radiation Therapy
|
|
Disease Site:
|
Gastrointestinal
|
|
Disease SubSite:
|
Gallbladder
|
|
Drug Provided:
|
-- none --
|
|
Comments:
|
|
|
Eligibility:
|
Histopathologically confirmed extrahepatic cholangiocarcinoma of the gallbladder or bile duct, meeting at least 1 of the following criteria: Pathological T2-4 disease, Pathological N1 disease, Positive margins (any T or N ). Must have undergone potentially curative radical resection with negative (R0) or microscopically positive (R1) margins within the past 56 days and recovered. No distant metastatic disease as indicated by a CT scan or MRI of the chest, abdomen, and pelvis within the past 42 days. Positive resected regional lymph nodes allowed, No ampullary cancer. Prior/Concurrent Therapy: see Disease Characteristics. No prior chemotherapy or radiotherapy for this disease, No prior upper abdominal radiotherapy.
|
|
Participating Sites:
|
Adventist Medical Center, Northwest Cancer Specialists, Providence Milwaukie Hospital, Providence Portland Medical Center, Providence St. Vincent Medical Center, Southwest Washington Medical Center
|
|
|
|
|
 |
|
 |
|
|
|